Themis Medicare, NFL Biosciences partner on smoking cessation candidate NFL-101
Indian pharmaceutical company Themis Medicare has joined hands with French biotech company NFL Biosciences to develop NFL-101, a drug candidate for smoking cessation for the Indian market. Themis Medicare submitted an investigational new drug application for NFL-101 phase 2/3 clinical trial to the Central Drugs Standard Control Organization, the National Regulatory Authority of India. After […]